Cargando…

Various Mechanisms Involve the Nuclear Factor (Erythroid-Derived 2)-Like (NRF2) to Achieve Cytoprotection in Long-Term Cisplatin-Treated Urothelial Carcinoma Cell Lines

Therapeutic efficacy of cisplatin-based chemotherapy for advanced-stage urothelial carcinoma (UC) is limited by drug resistance. The nuclear factor (erythroid-derived 2)-like 2 (NRF2) pathway is a major regulator of cytoprotective responses. We investigated its involvement in cisplatin resistance in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Skowron, Margaretha A., Niegisch, Günter, Albrecht, Philipp, van Koeveringe, Gommert, Romano, Andrea, Albers, Peter, Schulz, Wolfgang A., Hoffmann, Michèle J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5578070/ https://www.ncbi.nlm.nih.gov/pubmed/28767070 http://dx.doi.org/10.3390/ijms18081680

Ejemplares similares

Multifaceted Mechanisms of Cisplatin Resistance in Long-Term Treated Urothelial Carcinoma Cell Lines
por: Skowron, Margaretha A., et al.
Publicado: (2018)

Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells
por: Höhn, Annika, et al.
Publicado: (2016)

Phenotype plasticity rather than repopulation from CD90/CK14+ cancer stem cells leads to cisplatin resistance of urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2015)

Distinctive mutational spectrum and karyotype disruption in long-term cisplatin-treated urothelial carcinoma cell lines
por: Skowron, Margaretha A., et al.
Publicado: (2019)

Prodigiosin Sensitizes Sensitive and Resistant Urothelial Carcinoma Cells to Cisplatin Treatment
por: Berning, Lena, et al.
Publicado: (2021)

The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors
por: Hoffmann, Michèle J., et al.
Publicado: (2016)

Epigenetic Treatment of Urothelial Carcinoma Cells Sensitizes to Cisplatin Chemotherapy and PARP Inhibitor Treatment
por: Thy, Sophia, et al.
Publicado: (2021)

Multiple Mechanisms Mediate Resistance to Sorafenib in Urothelial Cancer
por: Knievel, Judith, et al.
Publicado: (2014)

Canonical Notch signalling is inactive in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines
por: Hölscher, Alexander S., et al.
Publicado: (2018)

Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines
por: Pinkerneil, Maria, et al.
Publicado: (2016)

Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
por: Lehmann, Maria, et al.
Publicado: (2014)

Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma
por: Droop, Johanna, et al.
Publicado: (2017)

Concomitant downregulation of the imprinted genes DLK1 and MEG3 at 14q32.2 by epigenetic mechanisms in urothelial carcinoma
por: Greife, Annemarie, et al.
Publicado: (2014)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

HERV-K and LINE-1 DNA Methylation and Reexpression in Urothelial Carcinoma
por: Kreimer, Ulrike, et al.
Publicado: (2013)

Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses
por: Torrente, L, et al.
Publicado: (2017)

Cytoprotection “gone astray”: Nrf2 and its role in cancer
por: Geismann, Claudia, et al.
Publicado: (2014)

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine
por: Isono, Makoto, et al.
Publicado: (2017)

Combination of Decitabine and Entinostat Synergistically Inhibits Urothelial Bladder Cancer Cells via Activation of FoxO1
por: Wang, Chenyin, et al.
Publicado: (2020)

Proteomic and transcriptomic profiles of human urothelial cancer cells with histone deacetylase 5 overexpression
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2022)

The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells
por: Heubach, Judith, et al.
Publicado: (2015)

Cytoprotective Nrf2 Pathway Is Induced In Chronically Txnrd 1-Deficient Hepatocytes
por: Suvorova, Elena S., et al.
Publicado: (2009)

The Role of Nrf2 and Cytoprotection in Regulating Chemotherapy Resistance of Human Leukemia Cells
por: Rushworth, Stuart A., et al.
Publicado: (2011)

Regulation of Wound Healing by the NRF2 Transcription Factor—More Than Cytoprotection
por: Hiebert, Paul, et al.
Publicado: (2019)

Cytoprotective Role of Nrf2 in Electrical Pulse Stimulated C2C12 Myotube
por: Horie, Masaki, et al.
Publicado: (2015)

Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines
por: Lang, Alexander, et al.
Publicado: (2020)

Fresh Medium or L-Cystine as an Effective Nrf2 Inducer for Cytoprotection in Cell Culture
por: Dai, Wujing, et al.
Publicado: (2023)

c‐Jun NH(2)‐Terminal Protein Kinase Phosphorylates the Nrf2‐ECH Homology 6 Domain of Nuclear Factor Erythroid 2–Related Factor 2 and Downregulates Cytoprotective Genes in Acetaminophen‐Induced Liver Injury in Mice
por: Chen, Yiping, et al.
Publicado: (2020)

Effects of novel HDAC inhibitors on urothelial carcinoma cells
por: Kaletsch, Aline, et al.
Publicado: (2018)

Competition of nuclear factor-erythroid 2 factors related transcription factor isoforms, Nrf1 and Nrf2, in antioxidant enzyme induction()
por: Chepelev, Nikolai L., et al.
Publicado: (2013)

The function of miRNA-153 against isoflurane-induced neurotoxicity via Nrf2/ARE cytoprotection
por: Shao, Dong, et al.
Publicado: (2019)

PARP2 poly(ADP-ribosyl)ates nuclear factor erythroid 2-related factor 2 (NRF2) affecting NRF2 subcellular localization
por: Jankó, Laura, et al.
Publicado: (2023)

The value of urodynamic tools to guide patient selection in sacral neuromodulation
por: Drossaerts, Jamie, et al.
Publicado: (2015)

Multidisciplinary treatment for functional urological disorders with psychosomatic comorbidity in a tertiary pelvic care center—A retrospective cohort study
por: van Knippenberg, Vera, et al.
Publicado: (2022)

Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
por: Hoffmann, Michèle J., et al.
Publicado: (2021)

Clinicopathological significance of nuclear factor (erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer
por: Kawasaki, Yota, et al.
Publicado: (2015)

Nuclear Factor-Erythroid 2-Related Factor 2 (Nrf2) and Mitochondrial Dynamics/Mitophagy in Neurological Diseases
por: Kang, Tae-Cheon
Publicado: (2020)

The Potential Role of Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) in Glaucoma: A Review
por: Wang, Mingxuan, et al.
Publicado: (2020)

HDAC5 Expression in Urothelial Carcinoma Cell Lines Inhibits Long-Term Proliferation but Can Promote Epithelial-to-Mesenchymal Transition
por: Jaguva Vasudevan, Ananda Ayyappan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qd4heg7hk7a3cnmdhh7pq80krl